Developer docs
API playgroundTry for free, no card

Search company profiles

Biofrontera

Full company profile

uuid00007dv

Namestring
Biofrontera
Legal namestring
Biofrontera Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Biofrontera Inc. is a US-headquartered, commercial-stage biopharmaceutical company specializing in photodynamic therapy (PDT) for dermatological conditions. The company commercializes Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, an FDA-approved photosensitizer applied to affected skin and activated by red light from the company's BF-RhodoLED lamp series to produce reactive oxygen species that destroy abnormal cells. Following the October 2025 strategic acquisition of all US rights from German parent Biofrontera AG for $11 million, Biofrontera Inc. now holds independent control of the NDA, IND, patents, trademarks, and manufacturing rights for Ameluz and RhodoLED in the United States, eliminating a prior earnout structure and improving gross margins by approximately 2,400 basis points.

The company serves two primary customer segments: dermatologists and healthcare providers who prescribe and administer PDT, and the patient populations they treat, including those with actinic keratosis (58 million Americans), basal cell carcinoma (3.6 million annual US diagnoses), and acne vulgaris (50 million Americans). Biofrontera generates revenue through direct product sales of Ameluz and RhodoLED via a US-focused sales organization led by a Chief Commercial Officer and Senior Vice President of Sales & Strategic Accounts, with additional contribution from the November 2025 divestiture of Xepi (ozenoxacin cream) to Pelthos Therapeutics for $3 million at closing plus up to $6 million in milestones. The company reported record full-year 2025 revenue of $41.7 million with Q4 2025 revenue of $17.1 million (36% year-over-year growth) and Q1 2026 revenue of $10.1 million (17% year-over-year growth).

The business model is a single-platform, indication-expansion model centered on Ameluz. Beyond the current face and scalp actinic keratosis indication, Biofrontera is pursuing three near-term growth vectors: an FDA-accepted supplemental NDA for superficial basal cell carcinoma with a September 28, 2026 PDUFA date; a planned Q3 2026 sNDA submission based on positive Phase 3 results in AK on extremities, neck, and trunk (45.6% complete clearance); and an FDA meeting planned for Q3 2026 following positive Phase 2b results in acne vulgaris (57.97% reduction in inflammatory lesions). Biofrontera is publicly traded on NASDAQ under ticker BFRI, with German parent Biofrontera AG remaining a significant shareholder.

Short descriptiontext

Biofrontera Inc. is a US biopharmaceutical company that commercializes Ameluz (an FDA-approved topical photosensitizer) combined with its BF-RhodoLED red-light lamp for photodynamic therapy of actinic keratosis, targeting dermatologists treating skin conditions including actinic keratosis, basal cell carcinoma, and acne.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
photodynamic therapy, dermatology pharmaceuticals, actinic keratosis treatment, topical photosensitizers, FDA-approved drug-device combination
Industry2 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Dermatology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales - Ameluz
TypeOne Time License
Description

Revenue from sales of FDA-approved Ameluz (aminolevulinic acid hydrochloride) topical gel for photodynamic therapy treatments in dermatology.

biospace.com
2Licensing and Milestone Payments - Xepi Divestiture
TypeLicensing Royalties
Description

Biofrontera sold its US license for Xepi antibiotic cream to Pelthos Therapeutics for $3 million at closing plus up to $6 million in milestone payments.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Ameluz
Description

Aminolevulinic acid hydrochloride topical gel, 10% - FDA-approved flagship drug for photodynamic therapy treatment of actinic keratoses

biofrontera-us.com
+2 more records
Core offering1 text field

Biofrontera commercializes a proprietary photodynamic therapy (PDT) drug-device combination consisting of Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, and the BF-RhodoLED red-light lamp, sold to dermatologists for the in-office treatment of actinic keratoses and related dermatological conditions. The company also pursues label expansion into superficial basal cell carcinoma and acne vulgaris and supplies the German parent Biofrontera AG's legacy products under transfer arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 45.6% complete clearance for actinic keratosis vs 16.7% for vehicle PDT in Phase 3 trial
+6 more records
Product and service2 records
1Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%
CategoryDermatology Pharmaceuticals
Description

FDA-approved topical photosensitizer drug applied to skin lesions and activated by the BF-RhodoLED red-light lamp during in-office photodynamic therapy; sold to dermatologists for treatment of actinic keratoses.

2BF-RhodoLED lamp series
CategoryMedical Devices
Description

Medical device that emits red light at specific wavelengths to activate aminolevulinic acid in Ameluz gel during photodynamic therapy; sold to dermatology practices as the device component of the Ameluz PDT drug-device combination.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-07
Description

Biofrontera sold its US license for Xepi antibiotic cream to Pelthos Therapeutics for $3 million at closing plus up to $6 million in potential milestone payments. The divestiture allows Biofrontera to focus on its photodynamic therapy platform.

2Biofrontera AG
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Biofrontera Inc. completed acquisition of all US rights to Ameluz and RhodoLED from Biofrontera AG, including drug applications, patents, trademarks, and manufacturing rights. The $11 million investment was led by existing investors and enables the company to independently manage US clinical development, manufacturing, and marketing.

globenewswire.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sun Pharmaceutical Industries
TypeDirect peer
Description

Sun Pharma is a direct competitor through its dermatology franchise (including the former DUSA Pharmaceuticals Levulan PDT franchise) and is also a known IP adversary to Biofrontera, having filed patent infringement claims against Ameluz. Both compete in dermatology with branded therapies sold through US dermatology channels.

TypeBroad incumbent
Description

Galderma is one of the largest pure-play dermatology companies globally, offering prescription and aesthetic dermatology products sold through the same dermatologist prescriber base Biofrontera targets. Its scale and broad portfolio make it a key incumbent competitor.

TypeEmerging player
Description

Dermavant is a late-stage dermatology company focused on inflammatory skin conditions (Vtama for psoriasis/atopic dermatitis). It targets the same US dermatology specialty channel and represents an emerging competitor with novel topical therapies.

TypeEmerging player
Description

Aclaris is a clinical-stage dermatology company developing novel immuno-inflammatory and oncologic dermatology therapies. It operates in the same dermatology specialty category with overlapping R&D focus on skin conditions.

TypeBroad incumbent
Description

Almirall is a dermatology-focused European pharma company with US commercial operations in dermatology (including the legacy Aqua Pharmaceuticals portfolio). It directly competes in the AK and medical dermatology space through overlapping US specialty sales channels.

TypeBroad incumbent
Description

LEO Pharma is a global dermatology-focused pharmaceutical company with a strong presence in actinic keratosis (e.g., Picato) and other skin conditions. It serves the same dermatology specialty channel as Biofrontera with branded prescription therapies.

TypeEmerging player
Description

Verrica is a dermatology therapeutics company developing topical treatments for skin diseases including molluscum contagiosum and actinic keratoses (its investigational VP-315). It overlaps with Biofrontera in the AK treatment space as an emerging PDT-adjacent competitor.

TypeEmerging player
Description

Sol-Gel is a dermatology company developing topical branded generics and innovative therapies for skin conditions including acne vulgaris. It directly overlaps with Biofrontera's acne indication expansion plans.

TypeBroad incumbent
Description

Ortho Dermatologics, the dermatology division of Bausch Health, markets prescription dermatology products (e.g., Solodyn, Retin-A Micro, Onexton) directly to US dermatologists. It is one of the largest established players competing for the same prescriber relationships and treatment slots.

TypeOthers
Description

Pelthos is a specialty pharmaceutical company that acquired Biofrontera's Xepi (ozenoxacin) antibiotic cream asset in November 2025. It is a transactional counterparty rather than a direct competitor but reflects overlap in the dermatology commercial ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biofrontera

Dermatology Pharmaceuticalsbiofrontera-us.com

Biofrontera Inc. is a US biopharmaceutical company that commercializes Ameluz (an FDA-approved topical photosensitizer) combined with its BF-RhodoLED red-light lamp for photodynamic therapy of actinic keratosis, targeting dermatologists treating skin conditions including actinic keratosis, basal cell carcinoma, and acne.

What Biofrontera does

Biofrontera Inc. is a US-headquartered, commercial-stage biopharmaceutical company specializing in photodynamic therapy (PDT) for dermatological conditions. The company commercializes Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, an FDA-approved photosensitizer applied to affected skin and activated by red light from the company's BF-RhodoLED lamp series to produce reactive oxygen species that destroy abnormal cells. Following the October 2025 strategic acquisition of all US rights from German parent Biofrontera AG for $11 million, Biofrontera Inc. now holds independent control of the NDA, IND, patents, trademarks, and manufacturing rights for Ameluz and RhodoLED in the United States, eliminating a prior earnout structure and improving gross margins by approximately 2,400 basis points.

The company serves two primary customer segments: dermatologists and healthcare providers who prescribe and administer PDT, and the patient populations they treat, including those with actinic keratosis (58 million Americans), basal cell carcinoma (3.6 million annual US diagnoses), and acne vulgaris (50 million Americans). Biofrontera generates revenue through direct product sales of Ameluz and RhodoLED via a US-focused sales organization led by a Chief Commercial Officer and Senior Vice President of Sales & Strategic Accounts, with additional contribution from the November 2025 divestiture of Xepi (ozenoxacin cream) to Pelthos Therapeutics for $3 million at closing plus up to $6 million in milestones. The company reported record full-year 2025 revenue of $41.7 million with Q4 2025 revenue of $17.1 million (36% year-over-year growth) and Q1 2026 revenue of $10.1 million (17% year-over-year growth).

The business model is a single-platform, indication-expansion model centered on Ameluz. Beyond the current face and scalp actinic keratosis indication, Biofrontera is pursuing three near-term growth vectors: an FDA-accepted supplemental NDA for superficial basal cell carcinoma with a September 28, 2026 PDUFA date; a planned Q3 2026 sNDA submission based on positive Phase 3 results in AK on extremities, neck, and trunk (45.6% complete clearance); and an FDA meeting planned for Q3 2026 following positive Phase 2b results in acne vulgaris (57.97% reduction in inflammatory lesions). Biofrontera is publicly traded on NASDAQ under ticker BFRI, with German parent Biofrontera AG remaining a significant shareholder.

Biofrontera firmographics

Firmographics
Name
Biofrontera
Legal name
Biofrontera Inc.
Website
https://biofrontera-us.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Biofrontera Inc. is a US biopharmaceutical company that commercializes Ameluz (an FDA-approved topical photosensitizer) combined with its BF-RhodoLED red-light lamp for photodynamic therapy of actinic keratosis, targeting dermatologists treating skin conditions including actinic keratosis, basal cell carcinoma, and acne.
Ownership category
akta.pro rank

Biofrontera industry classification

Industry
Product category
Dermatology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medical Equipment and Supplies Manufacturing (3391)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Photodynamic therapy
  • Dermatology pharmaceuticals
  • Actinic keratosis treatment
  • Topical photosensitizers
  • FDA-approved drug-device combination

Where Biofrontera is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Biofrontera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

  1. Product Sales - Ameluz: Revenue from sales of FDA-approved Ameluz (aminolevulinic acid hydrochloride) topical gel for photodynamic therapy treatments in dermatology.
  2. Licensing and Milestone Payments - Xepi Divestiture: Biofrontera sold its US license for Xepi antibiotic cream to Pelthos Therapeutics for $3 million at closing plus up to $6 million in milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Biofrontera product offering

Product offering

Core offering

Biofrontera commercializes a proprietary photodynamic therapy (PDT) drug-device combination consisting of Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, and the BF-RhodoLED red-light lamp, sold to dermatologists for the in-office treatment of actinic keratoses and related dermatological conditions. The company also pursues label expansion into superficial basal cell carcinoma and acne vulgaris and supplies the German parent Biofrontera AG's legacy products under transfer arrangements.

Differentiator

Problem solved

Functional benefit

Brands

  • Ameluz: Aminolevulinic acid hydrochloride topical gel, 10% - FDA-approved flagship drug for photodynamic therapy treatment of actinic keratoses
  • RhodoLED
  • Xepi

Products and services

  • Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% FDA-approved topical photosensitizer drug applied to skin lesions and activated by the BF-RhodoLED red-light lamp during in-office photodynamic therapy; sold to dermatologists for treatment of actinic keratoses.
  • BF-RhodoLED lamp series Medical device that emits red light at specific wavelengths to activate aminolevulinic acid in Ameluz gel during photodynamic therapy; sold to dermatology practices as the device component of the Ameluz PDT drug-device combination.

Quantifiable outcome

  • 45.6% complete clearance for actinic keratosis vs 16.7% for vehicle PDT in Phase 3 trial
  • +6 more outcomes

Companies that use Biofrontera

Customer profile

Segments2 records

Ideal customer profiles2 records

Biofrontera technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Biofrontera partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Pelthos Therapeutics Inc.minorOEM/ Whitelabel/ Licensing Partner · 7 November 2025Biofrontera sold its US license for Xepi antibiotic cream to Pelthos Therapeutics for $3 million at closing plus up to $6 million in potential milestone payments. The divestiture allows Biofrontera to focus on its photodynamic therapy platform.
  • Biofrontera AGcoreStrategic or Co-development Partner · 23 October 2025Biofrontera Inc. completed acquisition of all US rights to Ameluz and RhodoLED from Biofrontera AG, including drug applications, patents, trademarks, and manufacturing rights. The $11 million investment was led by existing investors and enables the company to independently manage US clinical development, manufacturing, and marketing.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Biofrontera competitors and assessment

Company assessment

Direct peers

  • Sun Pharmaceutical Industries: Sun Pharma is a direct competitor through its dermatology franchise (including the former DUSA Pharmaceuticals Levulan PDT franchise) and is also a known IP adversary to Biofrontera, having filed patent infringement claims against Ameluz. Both compete in dermatology with branded therapies sold through US dermatology channels.

Broad incumbents

  • Galderma: Galderma is one of the largest pure-play dermatology companies globally, offering prescription and aesthetic dermatology products sold through the same dermatologist prescriber base Biofrontera targets. Its scale and broad portfolio make it a key incumbent competitor.
  • Almirall: Almirall is a dermatology-focused European pharma company with US commercial operations in dermatology (including the legacy Aqua Pharmaceuticals portfolio). It directly competes in the AK and medical dermatology space through overlapping US specialty sales channels.
  • LEO Pharma: LEO Pharma is a global dermatology-focused pharmaceutical company with a strong presence in actinic keratosis (e.g., Picato) and other skin conditions. It serves the same dermatology specialty channel as Biofrontera with branded prescription therapies.
  • Bausch Health (Ortho Dermatologics): Ortho Dermatologics, the dermatology division of Bausch Health, markets prescription dermatology products (e.g., Solodyn, Retin-A Micro, Onexton) directly to US dermatologists. It is one of the largest established players competing for the same prescriber relationships and treatment slots.

Emerging players

  • Dermavant Sciences: Dermavant is a late-stage dermatology company focused on inflammatory skin conditions (Vtama for psoriasis/atopic dermatitis). It targets the same US dermatology specialty channel and represents an emerging competitor with novel topical therapies.
  • Aclaris Therapeutics: Aclaris is a clinical-stage dermatology company developing novel immuno-inflammatory and oncologic dermatology therapies. It operates in the same dermatology specialty category with overlapping R&D focus on skin conditions.
  • Verrica Pharmaceuticals: Verrica is a dermatology therapeutics company developing topical treatments for skin diseases including molluscum contagiosum and actinic keratoses (its investigational VP-315). It overlaps with Biofrontera in the AK treatment space as an emerging PDT-adjacent competitor.
  • Sol-Gel Technologies: Sol-Gel is a dermatology company developing topical branded generics and innovative therapies for skin conditions including acne vulgaris. It directly overlaps with Biofrontera's acne indication expansion plans.

Others

  • Pelthos Therapeutics: Pelthos is a specialty pharmaceutical company that acquired Biofrontera's Xepi (ozenoxacin) antibiotic cream asset in November 2025. It is a transactional counterparty rather than a direct competitor but reflects overlap in the dermatology commercial ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Biofrontera social profiles

Digital presence

Biofrontera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biofrontera leadership team

Management profile

Number of profiles

Profiles13 records

Biofrontera subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biofrontera funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biofrontera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biofrontera

What does Biofrontera do?

Biofrontera commercializes a proprietary photodynamic therapy (PDT) drug-device combination consisting of Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, and the BF-RhodoLED red-light lamp, sold to dermatologists for the in-office treatment of actinic keratoses and related dermatological conditions. The company also pursues label expansion into superficial basal cell carcinoma and acne vulgaris and supplies the German parent Biofrontera AG's legacy products under transfer arrangements.

Is Biofrontera a public or private company?

Biofrontera is a public company. It is classified as public and is currently operating.

When was Biofrontera founded?

Biofrontera was founded in 2015. It employs 51 to 100 people.

Where is Biofrontera based?

Biofrontera is headquartered in Woburn, United States, in the North America region.

How does Biofrontera make money?

Two revenue lines are on record. Product Sales - Ameluz is the primary driver. The others are licensing and Milestone Payments - Xepi Divestiture.

Who are Biofrontera's main competitors?

Sun Pharmaceutical Industries is listed as a direct peer. Broad incumbents are Galderma, Almirall, LEO Pharma and Bausch Health (Ortho Dermatologics). Emerging players are Dermavant Sciences, Aclaris Therapeutics, Verrica Pharmaceuticals and Sol-Gel Technologies. Pelthos Therapeutics is listed as an others.

Does Biofrontera have an API?

No public API is recorded for Biofrontera.

What industry is Biofrontera in?

Biofrontera's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolBiofrontera: 3 Key Takeaways for Long-Term InvestorsBiofrontera's Q3 2026 earnings call announced FDA approval of its topical gel Ameluz for superficial basal cell carcinoma, a second indication. The company also cleared customs for its redesigned lamp, restoring sales, but reported $3.2 million in cash and a going-concern warning. Management plans to draw on a line of credit and collect a milestone payment.The Motley FoolBiofrontera: 3 Key Takeaways for Long-Term InvestorsBiofrontera's Q3 2026 earnings call reported FDA approval of its topical gel Ameluz for superficial basal cell carcinoma, expanding its label. The company also cleared customs for its redesigned lamp, but cash reserves fell to $3.2 million, triggering a going-concern warning. Management plans to draw on a line of credit and collect a milestone payment.Quiver QuantitativeBiofrontera Inc. (BFRI) Stock Falls on Q3 2026 Earnings | BFRI Stock NewsBiofrontera Inc. reported Q3 2026 revenue of $9.1 million, up 29.8% year over year, but posted an operating loss of $6.5 million and a net loss of $6.4 million. The stock fell 8.5% after market close, and the company ended the quarter with $3.4 million in cash.TradingViewBFRI: sBCC approval expands Ameluz as ITC costs and liquidity pressure persistBiofrontera Inc. reported Q3 2026 revenue growth of 29.8% year-over-year, with sBCC approval and clearance of XL-C broadening commercial reach. Liquidity remains constrained, with substantial doubt about going concern despite planned mitigation actions.TradingViewBiofrontera Q3 2026 Earnings Call Is LiveBiofrontera's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.Business & FinancialBiofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven By 30% Year-Over-Year Revenue GrowthBiofrontera reported Q3 2026 net product revenue of $9.1 million, up 29.8% year-over-year, with a net loss of $6.4 million. The company also announced FDA approval of Ameluz for superficial basal cell carcinoma on September 9, 2026, and plans to begin commercialization in late 2026 into 2027.Quiver QuantitativeBiofrontera Revenue Rises 30% to $9.1 Million in Third Quarter | BFRIW Stock NewsBiofrontera reported third-quarter 2026 net product revenue of $9.1 million, up 29.8% year-over-year, with a net loss of $6.4 million. Gross margin rose to 74.4%, and the company received FDA approval for Ameluz PDT for superficial basal cell carcinoma on September 9, 2026.The future of tradingBiofrontera Q3 revenue rises 30% on higher Ameluz salesBiofrontera reported Q3 revenue of $9.1 million, up 30% year-over-year, with a net loss of $6.4 million. The company's Ameluz unit volume rose 23.3%, and it plans to commercialize Ameluz for sBCC in late 2026 to early 2027.YahooBiofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue GrowthBiofrontera reported Q3 2026 net product revenue of $9.1 million, up 29.8% year-over-year, with a net loss of $6.4 million. The company also received FDA approval for Ameluz to treat superficial basal cell carcinoma, and CBP ruled its redesigned XL-C lamp is not subject to the ITC exclusion order. It plans to begin commercializing Ameluz for sBCC in late 2026 into 2027.GlobeNewswireBiofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue GrowthBiofrontera reported Q3 2026 net product revenue of $9.1 million, up 29.8% year-over-year, with a net loss of $6.4 million. The company also received FDA approval for Ameluz PDT to treat superficial basal cell carcinoma on September 9, 2026, and plans to begin commercialization in the fourth quarter.